Gensight Biologics SA
Research Gensight Biologics SA (SIGHT) on Bullrun: market cap EUR 29.09M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSIGHT
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 29.09M
- Financial periodFY2025
- RevenueEUR 1.00K
- Revenue growth-99.9%
- Net income-EUR 12.04M
- Free cash flow-EUR 9.17M
Valuation Snapshot
latest market cap is EUR 29.09M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 1.00K | -EUR 12.04M | -EUR 9.17M | n/a | -0.08 | EUR 2.42M | EUR 12.86M | -EUR 24.94M |
| FY2024 | EUR 1.50M | -EUR 14.00M | -EUR 12.94M | n/a | -0.15 | EUR 2.46M | EUR 14.41M | -EUR 26.92M |
| FY2023 | EUR 1.27M | -EUR 26.22M | -EUR 24.67M | n/a | -0.54 | EUR 2.13M | EUR 18.43M | -EUR 30.70M |
| FY2022 | EUR 2.58M | -EUR 27.63M | -EUR 34.01M | n/a | -0.6 | EUR 10.61M | EUR 12.65M | -EUR 15.35M |
| FY2021 | EUR 5.28M | -EUR 28.62M | -EUR 17.17M | n/a | n/a | EUR 44.29M | n/a | EUR 15.99M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 29.09M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Gensight Biologics SA
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Gensight Biologics SA's market cap?
Gensight Biologics SA's market capitalization is EUR 29.09M.
What does Gensight Biologics SA do?
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms.